Erasca Names Former Genentech Oncology Head Fuchs as R&D President
ERAS has more than doubled off its 52-week low of $1.33.
Summary
Erasca appointed Dr. Charles S. Fuchs, former global head of oncology at Genentech/Roche, as President of R&D. Fuchs led development of multiple approved cancer drugs and most recently served as CMO of Tubulis. The hire brings deep GI cancer expertise to Erasca's RAS-targeting pipeline, which recently reported encouraging Phase 1 data for ERAS-0015. This follows a turbulent period including a securities lawsuit and a $632.5M follow-on offering in July. The appointment signals a push to strengthen clinical development capabilities ahead of potential commercialization.
At the time of this announcement, ERAS was trading at $18.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $1.33 to $24.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.